Background and Purpose Nonvariceal upper gastrointestinal bleeding (gastrointestinal) is potentially life-threatening. The study aimed to evaluate the clinical outcome in patients with upper gastrointestinal bleeding with a prior history of ischemic stroke.

Methods The 2021 National Inpatient Sample database was employed to identify 259025 patients diagnosed with non-variceal upper gastrointestinal bleeding. 1485 patients exhibited a prior diagnosis of ischemic stroke. Data analysis was conducted using Stata version 18 to determine the primary outcome of mortality and secondary outcomes of length of hospitalization, cost, and post-hospitalization care needs.

Results 259025 patients exhibited admissions due to non-variceal upper gastrointestinal bleed, and 1485 (0.57%) patients exhibited prior diagnoses of ischemic stroke. Patients with a history of ischemic stroke had a mean age was 72.35 years with higher comorbidities. Patients with a prior history of ischemic stroke had a higher risk of in-hospital mortality (OR 7.51,p<0.01). Length of hospitalization was longer by an mean of 5.68 days (p<0.01), and a higher need for discharge to a skilled nursing facility (OR 3.30, p<0.01). Race, median annual income, and geographical distribution were statistically noncontributory to the outcomes.

Conclusion Patients with a history of ischemic stroke who present with non-variceal upper gastrointestinal bleeding tend to be older and have a higher comorbidity index. Prior history of stroke is an independent factor that contributes to the increased mortality in patients presenting with non-variceal upper gastrointestinal bleeding. They experience increased mortality rates, prolonged hospitalizations, higher costs during hospitalization, and a greater likelihood of being discharged to a nursing facility.

The authors have declared no competing interest.

https://hcup-us.ahrq.gov/tools_software.jsp

none

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

It is openly availaible at the website "https://hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp" The data used in this study is publicly available, de-identified, and contains no personal identifiers. As such, no ethics committee or IRB approval was required for its use in research.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Disclosure

Drs. Anudeep Surendranath, MD, Anupam K Gupta, MD, Saurabh Singhal,MD, have no conflicts of interest or financial ties to disclose.No funding was received for this work.

https://hcup-us.ahrq.gov/tools_software.jsp The data used in this study is publicly available, de-identified, and contains no personal identifiers. As such, no ethics committee or IRB approval was required for its use in research.

https://hcup-us.ahrq.gov/tools_software.jsp